News – Page 931 – Endpoints News

Allergan/Editas finally kick off CRISPR trial — marking first in vivo test of the gene-editing technology

6 years ago

Following EMA, FDA restricts use of high-dose Xeljanz, warning of added risks for the blockbuster JAK

6 years ago

Vertex rushes to assure Wall Street that Jeff Leiden is keeping a hand on the reins as one analyst questions ...

6 years ago

Jupiter biotech scores $56M to defeat herpes, in a field littered with failure

6 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2019

6 years ago

Nektar takes a hit as the FDA swerves away from opioid reviews — leaving NKTR-181 in limbo

6 years ago

Boston's NeuroBo to use bruised Gemphire to make Nasdaq debut

6 years ago

ICER backs cost-effectiveness of Vascepa, Xarelto; Epizyme's lead drug wins speedy US review

6 years ago

PARP inhibitors sometimes work beyond BRCA-mutations, researchers may finally know why

6 years ago

What makes Hal Barron tick? Look at the people he’s teaming up with at GSK

6 years ago

Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role

6 years ago

A 2-year-old fledgling biotech steers into PhIII and nabs a quick $565M buyout deal

6 years ago

In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval

6 years ago

FDA’s Woodcock weighs in on role of NIH in drug development

6 years ago

Bristol-Myers does it again, disappointing investors with a surprise Opdivo PhIII failure as chemo combo flops

6 years ago

WHO endorses GSK's dolutegravir for HIV; Syapse collaborates with Pfizer on RWE

6 years ago

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

6 years ago

Laser-focused on colorectal cancer test, Freenome wins $160M from marquee VC pack led by RA, Polaris

6 years ago

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ ...

6 years ago

Novartis backs Harvard spinout's quest to build TCR repository in $48M round

6 years ago

Novartis, AstraZeneca vet Jonathan Symonds steers back to a top post in Big Pharma, this time at GSK

6 years ago

Intra-Cellular shares mauled as a firestorm of speculation over adcomm cancellation spreads across BioTwitter

6 years ago

FDA OKs Humira copycat from Merck, Samsung Bioepis — but they will wait 4 years to launch

6 years ago

Sharpless outlines FDA’s key priorities for advancing public health

6 years ago

First page Previous page 928 929 930931932 933 934 Next page Last page